Increased excitability in tat-transgenic mice: Role of tat in HIV-related neurological disorders

Neurobiology of Disease

Volumn 55, Issue , 2013, Pages 110-119

  Zucchini, Silvia ^a,b   Pittaluga, Anna ^c   Brocca Cofano, Egidio ^d   Summa, Maria ^c   Fabris, Marina ^d   De Michele, Rita ^d   Bonaccorsi, Angela ^d   Busatto, Graziella ^d   Barbanti Brodano, Giuseppe ^a   Altavilla, Giuseppe ^d   Verlengia, Gianluca ^a   Cifelli, Pierangelo ^a,e   Corallini, Alfredo ^a   Caputo, Antonella ^d   Simonato, Michele ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b Technopole of Ferrara   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e RiMED Foundation   (Italy)

Author keywords

HIV 1 associated neurocognitive disorders; HIV 1 tat transgenic mice; Kainate; Neurodegeneration; Seizures

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; KAINIC ACID; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; EXCITABILITY; EXOCYTOSIS; HIPPOCAMPUS; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MOUSE; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; TAT GENE; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE PRODUCTS, TAT; KAINIC ACID; MALE; MICE; MICE, TRANSGENIC; NERVOUS SYSTEM DISEASES; NEUROTRANSMITTER AGENTS; SEIZURES; STATISTICS, NONPARAMETRIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VESICULAR GLUTAMATE TRANSPORT PROTEINS;

EID: 84877636417     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.02.004     Document Type: Article

References (71)

1. Agrawal L., et al. Preventing HIV-1 Tat-induced neuronal apoptosis using antioxidant enzymes: mechanistic and therapeutic implications. Virology 2007, 363:462-472.
2. Agrawal L., et al. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiol. Dis. 2012, 45:657-670.
3. Aksenov M.Y., et al. Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci. Lett. 2001, 305(1):5-8.
4. Albini A., et al. HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13153-13158.
5. Altavilla G., et al. Morphological, histochemical, immunohistochemical, and ultrastructural characterization of tumors, dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice. Am. J. Pathol. 1999, 154:1231-1244.
6. Arya S.K., et al. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985, 229:69-73.
7. Bartolomei F., et al. Isolated, chronic, epilepsia partialis continua in an HIV-infected patient. Arch. Neurol. 1999, 56:111-114.
8. Behnisch T., et al. HIV secreted protein Tat prevents long-term potentiation in the hippocampal CA1 region. Brain Res. 2004, 1012:187-189.
9. Bonanno G., Raiteri M. Functional evidence for multiple GABAB receptor subtypes in the rat cerebral cortex. J. Pharmacol. Exp. Ther. 1993, 262:114-118.
10. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
11. Brailoiu G.C., et al. Excitatory effects of human immunodeficiency virus 1 Tat on cultured rat cerebral cortical neurons. Neuroscience 2008, 151:701-710.
12. Bregola G., et al. Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures. J. Neurosci. 2002, 22:10030-10038.
13. Bruce-Keller A.J., et al. Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia 2008, 56:1414-1427.
14. Chang H.C., et al. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997, 12:1421-1431.
15. Cheng J., et al. Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience 1998, 82:97-106.
16. Corallini A., et al. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res. 1993, 53:5569-5575.
17. Dore G.J., et al. Prospective analysis of seizure occurring in human immunodeficiency virus type-1 infection. J. NeuroAIDS 1996, 1:59-69.
18. Dunkley P.R., et al. A rapid method for isolation of synaptosomes on Percoll gradient. Brain Res. 1986, 372:115-129.
19. Ensoli B., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 1993, 67:277-287.
20. Eugenin E.A., et al. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J. Neurochem. 2003, 85:1299-1311.
21. Eugenin E.A., et al. HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3434-3438.
22. Everall I.P., et al. Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. Brain Pathol. 1999, 9:209-217.
23. Fadda P., et al. Reduction of corticostriatal glutamatergic fibers in basic fibroblast growth factor deficient mice is associated with hyperactivity and enhanced dopaminergic transmission. Biol. Psychiatry 2007, 62:235-242.
24. Feligioni M., et al. The human immunodeficiency virus-1 protein Tat and its discrete fragments evoke selective release of acetylcholine from human and rat cerebrocortical terminals through species-specific mechanisms. J. Neurosci. 2003, 23:6810-6818.
25. Ferrari A., et al. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol. Ther. 2003, 8:284-294.
26. Ferris M.J., et al. The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 2009, 159:1292-1299.
27. Flora G., et al. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp. Neurol. 2003, 179(1):60-70.
28. Frankel A.D., Pabo C.O. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
29. Gavriil E.S., et al. Tat mediates apoptosis in vivo in the rat central nervous system. Biochem. Biophys. Res. Commun. 2000, 267(1):252-256.
30. Giulian D., et al. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 1990, 250:1593-1596.
31. Gupta S., et al. HIV-Tat elicits microglial glutamate release: role of NAPDH oxidase and the cystine-glutamate antiporter. Neurosci. Lett. 2010, 485:233-236.
32. Haughey N.J., et al. Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein Tat. J. Neurochem. 1999, 73:1363-1374.
33. Haughey N.J., et al. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J. Neurochem. 2001, 78:457-467.
34. Hudson L., et al. Detection of human immunodeficiency virus regulatory protein Tat in CNS tissues. J. Neurovirol. 2000, 6:145-155.
35. Janumpalli S., et al. A point mutation (D79N) of the alpha2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine. J. Neurosci. 1998, 18:2004-2008.
36. Jones M., et al. Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement. J. Neuropathol. Exp. Neurol. 1998, 57(6):563-570.
37. Kaul M., et al. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ. 2005, 12:878-892.
38. Kim B.O., et al. Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am. J. Pathol. 2003, 162:1693-1707.
39. King J.E., et al. HIV Tat and neurotoxicity. Microbes Infect. 2006, 8:1347-1357.
40. Li W., et al. NMDA receptor activation by HIV-Tat protein is clade dependent. J. Neurosci. 2008, 28:12190-12198.
41. Lindl K.A., et al. HIV-1 associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J. Neuroimmune Pharmacol. 2010, 5:294-309.
42. Longordo F., et al. The human immunodeficiency virus-1 protein Tat upregulates NMDA receptor function by acting at mGluR1 receptors coexisting on human and rat brain noradrenergic neurons. J. Pharmacol. Exp. Ther. 2006, 317:1097-1105.
43. Luccini E., et al. N-methyl-d-aspartate autoreceptors respond to low and high agonist concentrations by facilitating, respectively, exocytosis and carrier-mediated release of glutamate in rat hippocampus. J. Neurosci. Res. 2007, 85:3657-3665.
44. Masliah E., et al. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann. Neurol. 1992, 32:321-329.
45. Mengozzi M., et al. Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood 1999, 93:1851-1857.
46. Minghetti L., et al. Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions. Neurochem. Res. 2004, 29:965-978.
47. Modi G., et al. New onset seizures in HIV-infected patients without intracranial mass lesions or meningitis-a clinical, radiological and SPECT scan study. J. Neurol. Sci. 2002, 202:29-34.
48. Musante V., et al. The HIV-1 viral protein Tat increases glutamate and decreases GABA exocytosis from human and mouse neocortical nerve endings. Cereb. Cortex 2010, 20:1974-1984.
49. 2+ ions. J. Neurochem. 2011, 117:516-527.
50. Muzzolini A., et al. Characterization of glutamate and [3H]d-aspartate outflow from various in vitro preparations of the rat hippocampus. Neurochem. Int. 1997, 31:113-124.
51. Nath A., Geiger J.D. Neurobiological aspects of HIV infections: neurotoxic mechanisms. Prog. Neurobiol. 1998, 54:19-33.
52. Navia B.A., Jordan B.D., Price R.W. The AIDS dementia complex: I. Clinical features. Ann. Neurol. 1986, 19:517-524.
53. Paradiso B., et al. Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7191-7196.
54. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, New York. Second edition.
55. Peng J., et al. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J. Neuroimmunol. 2010, 218(1-2):94-101.
56. Pittaluga A., et al. Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 2007, 53:27-36.
57. Prendergast M.A., et al. Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitive-site on the N-methyl-d-aspartate receptor. Brain Res. 2002, 954:300-307.
58. Raiteri L., Raiteri M. Synaptosomes still viable after 25years of superfusion. Neurochem. Res. 2000, 25:1265-1274.
59. Sabatier J.M., et al. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J. Virol. 1991, 65:961-967.
60. Schmued L.C., Hopkins K.J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 2000, 874:123-130.
61. Schwarze S.R., et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285(5433):1569-1572.
62. Selnes O.A. Memory loss in persons with HIV/AIDS: assessment and strategies for coping. AIDS Read. 2005, 15:289-292.
63. Singer E.J., et al. Neurological presentation of AIDS. Neurol. Clin. 2010, 28:253-275.
64. Tattevin P., et al. Confusion, memory disorders, and ophthalmoparesis in a patient with AIDS. Lancet 2006, 367:368.
65. Virgili M., et al. Protection from kainic acid neuropathological syndrome by NMDA receptor antagonists: effect of MK-801 and CGP 39551 on neurotransmitter and glial markers. Neuropharmacology 1992, 5:469-474.
66. Wessenligh S.L. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann. Neurol. 1993, 33:576-582.
67. Westendorp M.O., et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995, 375:497-500.
68. Zauli G., et al. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J. Biol. Chem. 2000, 275(6):4159-4165.
69. Zhu J., et al. HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J. Pharmacol. Exp. Ther. 2009, 329:1071-1083.
70. Zucchini S., et al. Neuroprotective activity of CHF3381, a putative N-methyl-d-aspartate receptor antagonist. NeuroReport 2002, 13:2071-2074.
71. Zucchini S., et al. FGF-2 overexpression increases excitability and seizure susceptibility but decreases seizure-induced cell loss. J. Neurosci. 2008, 49:13112-13124.